Condition (MeSH)
Pyoderma
ClinicalTrials.gov lists 43 trials for Pyoderma or a narrower condition beneath it. XOMA (US) LLC has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 43 trials are tagged with Pyoderma itself; the rest are tagged with a narrower condition beneath it.
When did Pyoderma trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 4 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 1 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pyoderma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 18 |
| Phase 3 | 8 |
| Phase 4 | 3 |
| Not applicable | 2 |
| Observational | 9 |
How many Pyoderma trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 17 |
| Terminated | 8 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pyoderma trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| XOMA (US) LLC | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| AbbVie | 2 |
| InflaRx GmbH | 2 |
| Arena Pharmaceuticals | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Pyoderma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Gevokizumab | 4 |
| Spesolimab | 2 |
| IFX-1 | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Adalimumab-US | 3 |
| gevokizumab open-label | 2 |
| SHR-1139 Injection | 2 |
| Secukinmab | 2 |
| IMP1 (EMLA 5% cream) | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pyoderma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| sepsis | 2 | 1 |
| Endocarditis | 1 | 1 |
| Erysipelas | 1 | 1 |
| Intervertebral discitis | 1 | 1 |
| Pneumonia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pyoderma? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS. | Gut | 1964 | Yes |
| Household Molecular Epidemiology of Streptococcus pyogenes Carriage and Infection in The Gambia. | The Journal of infectious diseases | 2025 | No |
| Streptococcus pyogenes carriage and infection within households in The Gambia: a longitudinal cohort study. | The Lancet. Microbe | 2024 | No |
| A regional initiative to reduce skin infections amongst aboriginal children living in remote communities of the Northern Territory, Australia. | PLoS neglected tropical diseases | 2009 | No |
| The global burden of group A streptococcal diseases. | The Lancet. Infectious diseases | 2005 | No |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.